Posted by Michael Wonder on 13 Feb 2024
Biogen received European Commission approval for Skyclarys (omaveloxolone), the first therapy to treat Friedreich’s ataxia
12 February 2024 - Biogen announced the European Commission has authorised Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
Skyclarys is the first treatment approved within the European Union for this rare, genetic, progressive neurodegenerative disease.
